RecruitingNot ApplicableNCT06615349

DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care

DigiPall; a Randomized Controlled Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care


Sponsor

David Blum

Enrollment

382 participants

Start Date

Jun 11, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study is to test if a system consisting of a wearable device measuring heartbeats and steps, together with daily communication with a chatbot on the smartphone asking the patients about their symptoms and giving tips, can reduce unplanned hospital readmissions and improve well-being in advanced cancer and severely ill patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Patients with established diagnosis of a metastatic cancer/severe illness with limited life expectancy receiving palliative care services
  • Estimated life expectancy \<24 months (physician's guess)/ \>3 months
  • Karnofsky Index ≥ 50% / ECOG≤ 2
  • Aged \>18 years
  • Owns and uses a smartphone
  • Give written informed consent

Exclusion Criteria2

  • Patients under curative treatment
  • Relevant cognitive impairment

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALDigiPall

DigiPall is an intervention combining a sensor-equipped wearable with a chatbot communicating via WhatsApp on the patient's smartphone. Patients will be asked two questions daily for their subjective rating through WhatsApp on their smartphone, worded slightly differently depending on the measured values for steps, heart rate and compliance as well as the patient's answer the day before.


Locations(1)

University Hospital Zurich

Zurich, Canton of Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06615349


Related Trials